Anna Sureda – VJRegenMed

CAR-T in DLBCL: 4-year follow-up data from ZUMA-1

Marta Palhas — Fri, 26 Feb 2021 14:08:28 +0000

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the four-year follow-up data from the pivotal ZUMA-1 trial of axicabtagene ciloleucel (axi-cel) in adult patients with refractory diffuse large B-cell lymphoma (DLBCL). The four-year overall survival rate among patients after a single infusion of axi-cel was 44%. These are very encouraging results considering the heavily pre-treated patient population included in the pivotal clinical trial. Furthermore, there were no additional toxicity signs reported in this long-term follow-up analysis. This interview took place during the 3rd European CAR T-cell Meeting.

Highlights from the 3rd European CAR T-cell Meeting

Marta Palhas — Fri, 26 Feb 2021 14:08:27 +0000

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, shares her highlights from the 3rd European CAR T-cell meeting. Dr Sureda found particularly interesting the sessions on CAR T-cell-related toxicities, patient-reported outcomes, and academic production of CAR T-cell products. In addition, Dr Sureda outlines the importance and value of the EBMT/EHA CAR T-cell meeting, which is the ideal environment to hear the latest updates in CAR T-cell therapy in Europe, but it also provides a global perspective. This interview took place during the 3rd European CAR T-cell Meeting.

The future of CAR T-cell therapy in lymphoma

admin_vjr_user — Fri, 26 Feb 2021 14:08:21 +0000

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the future directions of CAR T-cell therapy in lymphoma. The availability of CAR-T has modified the treatment algorithm for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Indications for CAR T-cell therapy will likely expand to earlier lines of treatment and other lymphomas. Dr Sureda is looking forward to the data from three Phase III clinical trials comparing CAR T-cell therapies with autologous stem cell transplantation in patients with primary refractory disease. Additionally, strategies to improve efficacy and toxicity are certainly desirable. This interview took place during the 3rd European CAR T-cell Meeting.

Selecting DLBCL patients for CAR T-cell therapies

admin_vjr_user — Thu, 08 Oct 2020 14:08:11 +0000

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses how patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) are selected for CAR T-cell therapies and the associated challenges. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).